Denial management software vs. outsourcing: what actually fixes the number

A practice with a rising denial rate usually reaches for one of two fixes: hire a revenue cycle management firm to work the denials, or buy denial management software and work them in-house. The pitch decks for both make the choice sound obvious. The actual economics, and the actual failure modes, do not divide as cleanly as either pitch suggests, and the number that decides it is rarely the one either side leads with.

Why the denial number is worse than it was three years ago

This is not a seasonal blip. The industry-wide initial denial rate has climbed from 10.2 percent in 2020 to 11.8 percent, according to Experian Health's State of Claims report, and the share of providers reporting denial rates above 10 percent has grown from roughly 30 percent in 2022 to 41 percent today. MGMA's own practice-management data puts the typical first-pass denial rate for physician practices between 9 and 12 percent, with behavioural health, orthopaedics, and physical therapy running well above that band. Denials are now the single most cited revenue cycle challenge among finance leaders, according to HFMA's 2026 Revenue Cycle Benchmark Report, which also puts the share of denials considered avoidable at roughly 90 percent.

That last figure is the one worth sitting with. If nine in ten denials are avoidable, the real question a denial management purchase should answer is not "how do we work denials faster" but "why is a preventable one reaching the payer at all". A tool or a vendor that only speeds up the appeal, without addressing why modifier 59 got left off a claim or why a unit count exceeded an MUE, is treating a symptom the practice will keep generating every month.

Outsourced denial management: what the fee actually buys

Outsourced revenue cycle firms typically charge a percentage of collections, most commonly somewhere between 3 and 9 percent depending on specialty mix and the breadth of services bundled in. The pitch is straightforward: the firm only gets paid when the practice gets paid, so its incentives are aligned with recovering revenue. That is true as far as it goes, but it describes an incentive to collect, not an incentive to work every claim equally.

A vendor paid a slice of what it recovers has a rational reason to prioritise the high-dollar, easy-to-win denial over the low-dollar or genuinely contested one, since both consume roughly the same staff time but pay out very differently. That is not a hypothetical; it is the structural critique raised repeatedly against percentage-of-collections pricing in revenue cycle procurement guidance, and it is worth asking any prospective vendor directly: what happens to a $180 denial that needs three follow-up calls, next to a $4,000 one that needs a single letter?

The industry itself is already responding to a version of this pressure. Ryan Hartman, director of revenue cycle for the healthcare analytics firm Kodiak Solutions, told HFMA in early 2026 that provider partners are noticeably more open to automating the mechanical parts of this work than they were even a year or two before:

I'm hearing people talk about using technology to help draft appeal letters. I'm hearing them talk about automating routine tasks and redirecting some of their people resources toward follow-up activities.

That is the trend line worth noticing: even the outsourced-services side of this market is buying software to do the repeatable part, rather than paying a human, at a percentage-of-collections rate, to retype the same citation into every letter.

Denial management software: what it actually needs to check

Denial management software solves the outsourcing model's fee-alignment problem by charging a flat, usage-independent price, so a $180 denial and a $4,000 denial get identical attention. But a flat fee only earns its keep if the tool is doing genuine payment-rule verification, not just tracking that a denial happened. Two products can both call themselves "denial management software" while one checks a claim against real, current NCCI PTP and MUE edit data and the other is a dashboard for logging CARC codes a biller already had to read off the remittance by hand.

This is why we built our own tool around the edit data rather than around a denial tracker. A single scrubbed claim on Denial7 is checked against the actual CMS NCCI PTP and MUE files, with the edit quarter shown on the verdict, and a code we hold no data for is reported as not checked, never as a silent pass. That distinction, stated plainly rather than assumed, is what separates prevention from a prettier way to log the same denial after it has already happened.

The rework cost the pricing debate usually skips

Whichever model a practice picks, there is a cost sitting underneath both: what it actually takes, in staff time, to rework one denied claim once it lands. Estimates from CAQH and MGMA data put that figure between roughly $25 and $118 per claim depending on complexity, and Kodiak Solutions' widely cited 2023 figure of about $57 per appeal, still used by HFMA as a working benchmark, sits comfortably inside that range. A practice billing $300,000 a month at the 11.8 percent national average denial rate is generating well over 300 denied claims monthly; at even the low end of that rework range, that is thousands of dollars a month in administrative cost before a single denied dollar has actually been recovered, and that is true whether a percentage-fee vendor or an in-house biller is the one doing the reworking.

Prevention versus recovery: the distinction most comparisons skip

Recovery tooling, whether outsourced or software, works a claim after the payer has already rejected it. Prevention tooling checks the claim before it is submitted, against the same rules the payer's own adjudication system will apply. MGMA's analysis of the current denial cycle points to coding and modifier errors as recurring, structural drivers, the kind a pre-submission check catches for free every time, rather than a pattern a recovery vendor discovers only after the tenth identical denial.

This is the honest case for pairing whichever recovery model a practice already runs with a free pre-submission scrub, rather than treating the two as competing purchases. A claim scrubbed before it leaves the building either confirms the coding is clean or catches the exact NCCI, MUE, or modifier problem that would otherwise become next month's denial, and it costs nothing to check regardless of which recovery vendor or software sits downstream of it.

What denial management software should let you verify, not just claim

• Which specific edit sets it checks against, by name (NCCI PTP, MUE, payer-specific rules), not just "denial prevention" as a category.
• Whether the edit data is dated, so a verdict from last quarter's file is distinguishable from a current one.
• Whether pricing is flat or usage-scaled, and whether that scaling changes the incentive to work a low-dollar claim.
• Whether appeal letter generation cites the actual denial reason and CMS rule, or produces generic boilerplate a reviewer has seen a thousand times.
• What the vendor names as not built, rather than what a sales page implies by omission.

On that last point, in the interest of the same honesty: Denial7's free tier includes the single-claim scrubber, every CARC and RARC denial page with a cited corrective action, and a throttled test API key. Batch scrubbing, saved claim history, and appeal letter generation are Pro features at a flat $49 a month, because those represent an ongoing cost to run, not a one-time gate. We check against CMS Medicare NCCI and MUE edits only; commercial payers run variants of these plus their own rules, so a clean Medicare-basis scrub does not guarantee a commercial payer will pay, and we do not have team seats or payer-specific edit sets yet. A fair comparison names its own gaps, not just a competitor's.

A short decision framework

1. If your practice's denials are concentrated in a small number of high-dollar, genuinely complex appeals, expert outsourced follow-up can be worth the percentage fee, particularly below the volume where a full-time biller makes sense.
2. If denials are spread across many mid-size claims, flat-fee software wins on incentive alignment: it costs the same to work the $180 denial as the $4,000 one.
3. Either way, pair whatever recovery model you run with a pre-submission scrub. Preventing a denial is always cheaper than the best-run recovery process for it.
4. Ask any vendor, ours included, exactly which edit sets it checks and how current the data is before comparing price. A cheap tool checking stale or shallow data is not actually cheaper once the denials it missed show up next month.

Frequently asked questions

Is denial management software worth it for a small practice?

It depends on volume more than practice size. A small practice with a handful of denials a month may not need a dedicated tool at all; the free, single-claim scrub and the CARC/RARC lookup cover that case. Once denials are recurring weekly, the flat-fee cost of software usually undercuts the equivalent staff time spent reworking claims by hand.

Does outsourcing denial management always cost more than software?

Not necessarily in total dollars, particularly at high collection volumes, but the cost scales with revenue under a percentage-of-collections model, while flat-fee software cost stays fixed. The comparison that matters is not which is cheaper in isolation, but which one still gives the small, complex denial proper attention once the fee structure's incentives are accounted for.

Can denial management software replace a human biller?

No. Software can check a claim against published, mechanical payment rules and generate the cited appeal artefact, but it does not replace the judgement calls, payer relationship knowledge, and complex-appeal follow-up a human biller or an outsourced specialist brings. Treat it as the layer that removes the preventable, mechanical denials so human attention goes to the ones that actually need it.

What is the single biggest factor in choosing between the two models?

Whether the tool or vendor prevents denials before submission, not just works them after the fact. With roughly 90 percent of denials considered avoidable industry-wide, a purchase that only speeds up recovery is optimising the smaller half of the problem.